Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

Abstract Views: 1033
PDF: 861
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Hepatitis B virus (HBV) is a DNA virus transmitted predominantly by sexual contact or percutaneous exposure. HBV infection is by far the most common chronic viral infection affecting the liver in the world, and a leading cause of cirrhosis and hepatocellular carcinoma. Reactivation of HBV replication in patients undergoing immunosuppressive therapy is a well recognised and frequently reported complication of considerable clinical importance. The consequences of hepatic injury in these patients may range from asymptomatic liver function disturbances to massive hepatic necrosis, liver failure, and death (1-2).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Zingarelli, S., Airò, P., Frassi, M., Bazzani, C., Scarsi, M., & Puoti, M. (2008). Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo, 60(1), 22–27. https://doi.org/10.4081/reumatismo.2008.22